| Project/Area Number |
23790988
|
|---|
| Research Category |
Grant-in-Aid for Young Scientists (B)
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
Neurology
|
|---|
| Research Institution | Shiga University of Medical Science |
|---|
Principal Investigator |
|
|---|
| Co-Investigator(Renkei-kenkyūsha) |
KOJIMA Hideto 滋賀医科大学, 医学部, 教授 (00225434)
|
|---|
| Project Period (FY) |
2011 – 2013
|
| Project Status |
Completed (Fiscal Year 2013)
|
| Budget Amount *help |
¥4,160,000 (Direct Cost: ¥3,200,000、Indirect Cost: ¥960,000)
Fiscal Year 2013: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2012: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2011: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
|
|---|
| Keywords | 分子治療 / 遺伝子治療 / イメージング / 組織特異的ペプチド / 標的化 / 組織特異性 / 運動神経細胞 / 後根神経節細胞 / ターゲッティング / SOD1 |
|---|
| Research Abstract |
Engineering the new strategy of imaging or molecular therapy for spinal cord, we investigated to identify the specific peptides to bind with spinal cord. At last, we identified two kinds of peptides, which had high affinity with spinal cord. Next, we tried the examination for the imaging of spinal cord with using the peptides. Unfortunately, we couldn't success to establish the new imaging method with the peptides because the sensitivities had some problems. However, we succeeded the targeting to spinal cord with the peptides, which could effectively deliver the small oligonucleotides to spinal cord. This strategy has high potential to realize the new molecular therapy for non-curable neurological disease, which is expected to be arranged to more suitable condition for the neurodegenerative diseases.
|
